Gufic Biosciences (509079) Q4 24/25 earnings summary

Executive summary

• Strategic focus on critical care, fertility, aesthetics, neuro care, and international expansion, with targeted sales force realignment, evidence-based product launches, and leadership appointments to drive growth.

• Indore facility operational, absorbing higher fixed costs, expected to reach EBITDA break-even in FY26 and margin-accretive/full profitability by FY27.

• Strong R&D pipeline, new partnerships, and focus on regulated markets underpin long-term growth.

• Audited standalone and consolidated financial results for FY25 approved with unmodified opinion; final dividend of 10% (Re. 0.10 per share) recommended.

• Board approved new cost and secretarial auditors and additional investments in subsidiaries in India, UAE, and Ireland.

Financial highlights

• Q4 FY25 revenue: Rs 205 Cr (up from Rs 195 Cr YoY); EBITDA: Rs 27 Cr (up from Rs 5.1 Cr YoY); PAT: Rs 8 Cr (down from Rs 20 Cr YoY).

• FY25 revenue: Rs 819.8 Cr (up from Rs 806.7 Cr YoY); EBITDA: Rs 138.6 Cr (down from Rs 148 Cr YoY); PAT: Rs 69.9 Cr (down from Rs 86.2 Cr YoY).

• Consolidated revenue for FY25: Rs 82,343.24 lakhs (up from Rs 80,884.29 lakhs); net profit: Rs 6,964.87 lakhs (down from Rs 8,613.55 lakhs).

• Basic and diluted EPS for FY25: Rs 6.95 (down from Rs 8.74 YoY); total comprehensive income: Rs 6,952.18 lakhs (down from Rs 8,573.17 lakhs).

• Cash and cash equivalents increased to Rs 1,572.33 lakhs as of March 31, 2025.

Outlook and guidance

• Indore facility to reach EBITDA break-even in FY26, with full profitability/margin-accretion by FY27 as capacity ramps to 30%.

• International business expected to reach 25% of total revenue in 2-3 years, with export revenue projected to grow 1.5x-2x in 3-5 years.

• Board recommended a final dividend and approved further investments in subsidiaries to expand international presence.